Provided by Tiger Fintech (Singapore) Pte. Ltd.

CorMedix Inc.

8.35
+0.21002.58%
Volume:871.09K
Turnover:7.20M
Market Cap:544.27M
PE:-27.42
High:8.43
Open:8.14
Low:8.04
Close:8.14
Loading ...

Investors in CorMedix (NASDAQ:CRMD) have seen decent returns of 81% over the past five years

Simply Wall St.
·
17 Apr

RBC stays bullish on CorMedix as Q1 preliminary revenue reassures on near-term

TIPRANKS
·
08 Apr

CorMedix Shares Gain After 1Q Preliminary Sales Beat Views

Dow Jones
·
08 Apr

CorMedix Is Maintained at Buy by D. Boral Capital

Dow Jones
·
08 Apr

CorMedix Sees Q1 Net Sales of $39 Million; Boosts H1 Net Sales Guidance

MT Newswires Live
·
08 Apr

CorMedix Announces Preliminary Revenue Of $39M For 1Q 2025 Vs. Consensus Of $32.20M, And Expects 1Q 2025 Adjusted EBITDA (To Exceed $22.5M Once Final Numbers Are Reported)

Benzinga
·
08 Apr

CorMedix Inc - Increases H1 2025 Net Sales Guidance to $62 Million-$70 Million

THOMSON REUTERS
·
08 Apr

CorMedix Inc. Announces Preliminary First Quarter 2025 Results and Raises H1 2025 Net Sales Guidance

THOMSON REUTERS
·
08 Apr

Cormedix Inc. Announces Preliminary First Quarter 2025 Results and Raises H1 2025 Net Sales Guidance

GlobeNewswire
·
08 Apr

RBC Capital Remains a Buy on Cormedix (CRMD)

TIPRANKS
·
05 Apr

CorMedix Inc. to Participate in the 24th Annual Needham Virtual Healthcare Conference

GlobeNewswire
·
02 Apr

CorMedix Inc. Reports Record Q4 Earnings and Growth

TIPRANKS
·
29 Mar

Truist Financial Reaffirms Their Buy Rating on Cormedix (CRMD)

TIPRANKS
·
27 Mar

CorMedix Price Target Maintained With a $12.00/Share by RBC Capital

Dow Jones
·
26 Mar

RBC Capital Sticks to Its Buy Rating for Cormedix (CRMD)

TIPRANKS
·
26 Mar

U.S. RESEARCH ROUNDUP-Ashland, Connectone Bancorp, Neurocrine Biosciences

Reuters
·
26 Mar

Cormedix Inc (CRMD) Q4 2024 Earnings Call Highlights: A Profitable Quarter Amidst Strategic ...

GuruFocus.com
·
26 Mar

CorMedix Inc : Needham Cuts Target Price to $12 From $18

THOMSON REUTERS
·
26 Mar

CorMedix (CRMD) Q4 2024 Earnings Call Transcript

Motley Fool Transcribing
·
26 Mar

Needham Cuts CorMedix's Price Target to $12 from $18, Keeps Buy Rating

MT Newswires Live
·
26 Mar